• The race to extend the human healthspan is heating up. • What began as a niche biohacking movement has evolved into a rapidly growing ecosystem spanning early disease screenings, stem cell preservation, hormone support, and next-gen therapeutics. • Momentum is building as leading companies move from research toward validation. • Altos Labs, which raised a whopping $3B in 2022, is advancing preclinical programs and expanding into senescence-targeting therapies through its May acquisition of Dorian Therapeutics. • Meanwhile, Sam Altman-backed Retro Biosciences partnered with OpenAI in early 2025 to develop an AI model that helps design proteins capable of repairing cells - a key step toward slowing or reversing aging. • Consumer demand is also surging.

Article Summaries:

  • The race to extend the human healthspan is heating up. What began as a niche biohacking movement has evolved into a rapidly growing ecosystem spanning early disease screenings, stem cell preservation, hormone support, and next-gen therapeutics. Momentum is building as leading companies move from research toward validation. Altos Labs, which raised a whopping $3B in 2022, is advancing preclinical programs and expanding into senescence-targeting therapies through its May acquisition of Dorian Therapeutics. Meanwhile, Sam Altman-backed Retro Biosciences partnered with OpenAI in early 2025 to deve

Sources: